A seasoned biopharmaceutical entrepreneur and leader with over 25 years of experience across translational research, business strategy, global development, and project leadership

Former CEO and co-founder of Oak Hill Bio Limited, a clinical-stage rare disease company that raised $49M and secured multiple assets from a top 10 pharmaceutical company. Former COO and Board of a SPAC, raising $138M in trust, and acquiring Zura Bio. Former EVP of Translational Science at Cambrian Biopharma, a hybrid venture capital company focused on age-related diseases. Former VP and Head of Search and Rare Translational Science at Takeda Pharmaceuticals where he conceptualized and led the TAK–celerator™ initiative, an incubator-like model aimed at developing and externalizing rare disease therapies. Currently advising nascent companies in immunology and rare disease field